Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates

Gunn et al. show that the commercially available Ebola virus vaccine leads to sustained protection in a macaque model of partial protection when antibodies are directed against the soluble glycoprotein of Ebola, a target previously thought to have a minimal role in protection against disease.

Read the full article here

Related Articles